{"id":"NCT00707993","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics","officialTitle":"A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2010-08","completion":"2010-08","firstPosted":"2008-07-02","resultsPosted":"2013-05-24","lastUpdate":"2013-05-24"},"enrollment":441,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Alogliptin","otherNames":["SYR110322","SYR-322"]},{"type":"DRUG","name":"Glipizide","otherNames":["Glucotrol"]}],"arms":[{"label":"Alogliptin 25 mg QD","type":"EXPERIMENTAL"},{"label":"Glipizide 5 mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), compared to glipizide in elderly diabetic patients who have not received treatment or are on a single oral medication.","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin at Week 52.","timeFrame":"Baseline and Week 52.","effectByArm":[{"arm":"Alogliptin 25 mg QD","deltaMin":-0.14,"sd":0.063},{"arm":"Glipizide 5 mg QD","deltaMin":-0.09,"sd":0.067}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":21},"locations":{"siteCount":80,"countries":["United States","Hungary","India","Israel","Mexico","Peru","Poland","Romania","Russia","South Africa","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":222},"commonTop":["Urinary tract infection","Dizziness","Headache","Diarrhoea","Nasopharyngitis"]}}